{"id":"trilaciclib-carboplatin-etoposide-or-topotecan","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Trilaciclib works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for cell cycle progression. By blocking these kinases, trilaciclib prevents cancer cells from dividing and growing. This mechanism is particularly effective in combination with chemotherapy agents like carboplatin and etoposide.","oneSentence":"Trilaciclib is a CDK4/6 inhibitor that blocks cell cycle progression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:34.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Extensive-stage small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04902885","phase":"PHASE3","title":"Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-05-25","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":95},{"nctId":"NCT05071703","phase":"PHASE4","title":"Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-08-11","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":30},{"nctId":"NCT04504513","phase":"","title":"Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"G1 Therapeutics, Inc.","startDate":"","conditions":"Myelosuppression Adult, Chemotherapeutic Toxicity, Small Cell Lung Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3582,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trilaciclib plus chemotherapy"],"phase":"phase_3","status":"active","brandName":"Trilaciclib, carboplatin, etoposide，or Topotecan","genericName":"Trilaciclib, carboplatin, etoposide，or Topotecan","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trilaciclib is a CDK4/6 inhibitor that blocks cell cycle progression. Used for Small cell lung cancer, Extensive-stage small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}